Frontotemporal lobar degeneration (FTLD), predominantly comprised of tau and TDP-43 proteinopathies, is a common cause of early-onset dementia. Biomarkers that reliably classify FTLD subtypes are limited, thereby hindering in-vivo diagnosis and clinical trial stratification. We conducted large-scale, multi-platform cer...
R. Saloner, L. Cornelis, Joshua Downer et al.· bioRxiv· 0 citations
Cognitive and behavioral dysfunction in frontotemporal dementia (FTD) evolves along a clinical continuum from a clinically silent stage of disease, through a prodromal period, often referred to as mild cognitive impairment (MCI) and/or mild behavioral impairment (MBI), and into a clinically manifest stage recognized by...
M. Benatar, E. Huey, Chiadikaobi Onyike et al.· Brain : a journal of neurolo...· 1 citation
An international workshop was convened in London, Canada in 2025 to review the evidence for existing or evolving biomarkers suitable for the detection of either ALS or FTD pathobiology prior to phenoconversion and/or predict phenoconversion in at risk individuals.
Michael J. Strong, Neil S. Donison, A. Al-Chalabi et al.· Brain : a journal of neurolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.